Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1935 2
1936 1
1940 1
1946 1
1947 2
1948 3
1950 1
1961 5
1962 2
1963 2
1964 4
1965 2
1966 4
1967 1
1968 2
1969 2
1970 3
1971 2
1972 2
1973 1
1974 3
1975 3
1976 1
1977 4
1978 3
1979 1
1980 1
1981 1
1982 5
1985 4
1986 5
1987 5
1988 10
1989 15
1990 15
1991 19
1992 24
1993 19
1994 29
1995 14
1996 34
1997 23
1998 34
1999 42
2000 46
2001 65
2002 71
2003 93
2004 117
2005 153
2006 174
2007 205
2008 220
2009 278
2010 309
2011 377
2012 405
2013 461
2014 435
2015 472
2016 498
2017 562
2018 551
2019 528
2020 581
2021 573
2022 538
2023 140
Text availability
Article attribute
Article type
Publication date

Search Results

7,226 results
Results by year
Filters applied: . Clear all
Page 1
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, Barlesi F, Lee DH, Ares LP, Hsieh RW, Patil NS, Twomey P, Yang X, Meng R, Johnson ML. Cho BC, et al. Among authors: lee dh. Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576957 Clinical Trial.
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Houvras Y, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Kong S, Zalutskaya A, Louie-Gao M, Boral AL, Mazières J. Griesinger F, et al. Among authors: lee dh. Ann Oncol. 2022 Nov;33(11):1168-1178. doi: 10.1016/j.annonc.2022.08.002. Epub 2022 Aug 13. Ann Oncol. 2022. PMID: 35973665 Free article. Clinical Trial.
Wavelength-tunable spiral-phase-contrast imaging.
Lee DH, Lee S, Yeo WJ, Jeong SK, Jeon M, Choi HJ, Kim HS, Bae JY, Kim DU, Hur H, Hyun S, Lee KS, Chang KS, Lee W, Pak S, Kim GH, Kim IJ. Lee DH, et al. Opt Express. 2022 Jul 18;30(15):27273-27284. doi: 10.1364/OE.461660. Opt Express. 2022. PMID: 36236901 Free article.
High-Resolution 3D Printing for Electronics.
Park YG, Yun I, Chung WG, Park W, Lee DH, Park JU. Park YG, et al. Among authors: lee dh. Adv Sci (Weinh). 2022 Mar;9(8):e2104623. doi: 10.1002/advs.202104623. Epub 2022 Jan 17. Adv Sci (Weinh). 2022. PMID: 35038249 Free PMC article. Review.
Neuroinflammation in Post-Traumatic Stress Disorder.
Lee DH, Lee JY, Hong DY, Lee EC, Park SW, Lee MR, Oh JS. Lee DH, et al. Biomedicines. 2022 Apr 20;10(5):953. doi: 10.3390/biomedicines10050953. Biomedicines. 2022. PMID: 35625690 Free PMC article. Review.
7,226 results